| Name | Title | Contact Details |
|---|
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services.
Voyage Medical is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
AliveCor, Inc. is pioneering the creation of FDA-cleared machine learning techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. The FDA-cleared KardiaMobile is the most clinically validated mobile EKG solution on the market. It is recommended by leading cardiologists and used by people worldwide for accurate EKG recordings. KardiaMobile, and KardiaBand, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an EKG. Kardia is the first A.I. enabled platform to help clinicians manage patients for the early detection of atrial fibrillation, the most common cardiac arrhythmia and one that leads to a five times greater risk of stroke. KardiaBand is the first FDA-cleared medical device accessory for Apple Watch. AliveCor is recognized by FastCompany as 2018`s No. 1 most innovative company in artificial intelligence. AliveCor is a privately-held venture backed company headquartered in Mountain View, Calif.
We believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. We seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. Working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right dose to the patient who does.
VisCardia Inc is a privately held medical device company in Portland Oregon developing a novel chronic heart failure therapy. Our proprietary implantable system uses the patient’s own thoracic musculature to improve cardiac filling and output.